SRSF1 promotes proliferation, invasion and migration of esophageal squamous cell carcinoma Eca9706 cells by regulating VEGFA mRNA alternative splicing

doi:10.19401/j.cnki.1007-3639.2022.03.001

Abstract

Abstract:

Background and purpose: Serine/arginine-rich splicing factor 1 (SRSF1) is closely related to the development of tumor. Esophageal carcinoma is the common malignant tumor of digestive system. However, the role of SRSF1 in esophageal carcinoma is rarely reported. This study aimed to detect the expression of SRSF1 in esophageal squamous cell carcinoma (ESCC) and its effects on the proliferation, invasion and migration of ESCC cells, and to explore its mechanism. Methods: Forty pairs of ESCC tissues and paracancerous tissues resected at the Fourth Hospital of Hebei Medical University from January 2020 to December 2021 were collected for this study. The expression of SRSF1 in ESCC was detected by immunohistochemistry. The mRNA expression and protein level of SRSF1 in ESCC cells were detected by real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR) and Western blot, respectively. Eca9706 cell with high expression of SRSF1 was selected. The mRNA expression of SRSF1 was reduced by small interfering RNA (siRNA). The proliferation, migration and invasion of Eca9706 cells were detected by cell counting kit-8 (CCK-8), transwell and Matrigel matrix gel assays, respectively. Database was used to analyze the expression of vascular endothelial growth factor A (VEGFA) in ESCC tissues, and the correlation between expressions of SRSF1 and VEGFA was also analyzed. RTFQ-PCR was used to detect the expression levels of VEGFA Iso8a and Iso8b isoform in Eca9706 cells, and the change in VEGFA Iso8a and Iso8b isoform expressions was also detected after knocking down SRSF1. Results: The expression of SRSF1 was significantly higher in ESCC tissues than in normal esophageal tissues (P<0.05). SRSF1 mRNA and protein were highly expressed in Eca9706 cells (both P<0.01). The mRNA expression and protein level of SRSF1 was significantly lower in siRNA-SRSF1 group than in siRNA-NC group (P<0.01). After knocking down SRSF1, the proliferation, migration and invasion abilities of Eca9706 cells were significantly lower compared with siRNA-NC group (all P<0.05). The expression of VEGFA was significantly higher in ESCC tissue than in normal esophageal tissue (P<0.05), and it was positively correlated with the expression of SRSF1 (P<0.01). RTFQ-PCR showed that the level of VEGFA Iso8a expression in Eca9706 cells was significantly higher compared with VEGFA Iso8b (P<0.01). Moreover, the level of VEGFA Iso8a expression was significantly decreased, while the level of VEGFA Iso8b expression increased after knocking down SRSF1 (P<0.01). Conclusion: SRSF1 can promote proliferation, invasion and migration of ESCC Eca9706 cells by possibly regulating VEGFA mRNA splicing.

Key words: Esophageal squamous cell carcinoma, Serine/arginine-rich splicing factor 1, Vascular endothelial growth factor A, Cell proliferation, Cell migration, Cell invasion

CLC Number:

R735.1

DUAN Yuqing, XIA Ning, JIA Yunlong, ZHENG Wenya, LIU Lihua. SRSF1 promotes proliferation, invasion and migration of esophageal squamous cell carcinoma Eca9706 cells by regulating VEGFA mRNA alternative splicing[J]. China Oncology, 2022, 32(3): 191-199.

Figures/Tables 7

Fig. 1

Tab. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

References 25

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.v68.6
[2]	YANG Y M, HONG P, XU W W, et al. Advances in targeted therapy for esophageal cancer[J]. Signal Transduct Target Ther, 2020, 5(1): 229. doi: 10.1038/s41392-020-00323-3
[3]	ARNOLD M, SOERJOMATARAM I, FERLAY J, et al. Global incidence of oesophageal cancer by histological subtype in 2012[J]. Gut, 2015, 64(3): 381-387. doi: 10.1136/gutjnl-2014-308124
[4]	CHUNG C S, LEE Y C, WU M S. Prevention strategies for esophageal cancer: perspectives of the east vs west[J]. Best Pract Res Clin Gastroenterol, 2015, 29(6): 869-883. doi: 10.1016/j.bpg.2015.09.010
[5]	NOONE A M, CRONIN K A, ALTEKRUSE S F, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 632-641. doi: 10.1158/1055-9965.EPI-16-0520
[6]	YANG X P, COULOMBE-HUNTINGTON J, KANG S L, et al. Widespread expansion of protein interaction capabilities by alternative splicing[J]. Cell, 2016, 164(4): 805-817. doi: 10.1016/j.cell.2016.01.029
[7]	PELLARIN I, DALL'ACQUA A, GAMBELLI A, et al. Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity[J]. Oncogene, 2020, 39(22): 4390-4403. doi: 10.1038/s41388-020-1292-6
[8]	ANANDE G, DESHPANDE N P, MARESCHAL S, et al. RNA splicing alterations induce a cellular stress response associated with poor prognosis in acute myeloid leukemia[J]. Clin Cancer Res, 2020, 26(14): 3597-3607. doi: 10.1158/1078-0432.CCR-20-0184
[9]	SANFORD J R, WANG X, MORT M, et al. Splicing factor SFRS1 recognizes a functionally diverse landscape of RNA transcripts[J]. Genome Res, 2009, 19(3): 381-394. doi: 10.1101/gr.082503.108
[10]	ZHOU X X, WANG R, LI X B, et al. Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B[J]. J Clin Invest, 2019, 129(2): 676-693. doi: 10.1172/JCI120279
[11]	HUANG J, XU J M, CHEN Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 832-842. doi: 10.1016/S1470-2045(20)30110-8
[12]	LUO H Y, LU J, BAI Y X, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. doi: 10.1001/jama.2021.12836
[13]	CARTEGNI L, CHEW S L, KRAINER A R. Listening to silence and understanding nonsense: exonic mutations that affect splicing[J]. Nat Rev Genet, 2002, 3(4): 285-298. doi: 10.1038/nrg775
[14]	WU H, SUN S Y, TU K, et al. A splicing-independent function of SF2/ASF in microRNA processing[J]. Mol Cell, 2010, 38(1): 67-77. doi: 10.1016/j.molcel.2010.02.021
[15]	MARTÍNEZ-TERROBA E, EZPONDA T, BÉRTOLO C, et al. The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer[J]. Lab Invest, 2018, 98(12): 1562-1574. doi: 10.1038/s41374-018-0128-2
[16]	DUAN Y Q, JIA Y L, WANG J L, et al. Long noncoding RNA DGCR5 involves in tumorigenesis of esophageal squamous cell carcinoma via SRSF1-mediated alternative splicing of Mcl-1[J]. Cell Death Dis, 2021, 12(6): 587. doi: 10.1038/s41419-021-03858-7
[17]	PASCHALIS A, SHARP A, WELTI J C, et al. Alternative splicing in prostate cancer[J]. Nat Rev Clin Oncol, 2018, 15(11): 663-675. doi: 10.1038/s41571-018-0085-0
[18]	BIEGING-ROLETT K T, KAISER A M, MORGENS D W, et al. Zmat3 is a key splicing regulator in the p53 tumor suppression program[J]. Mol Cell, 2020, 80(3): 452-469. e9.
[19]	CHEN L L, LUO C L, SHEN L, et al. SRSF1 prevents DNA damage and promotes tumorigenesis through regulation of DBF4B pre-mRNA splicing[J]. Cell Rep, 2017, 21(12): 3406-3413. doi: 10.1016/j.celrep.2017.11.091
[20]	WANG J L, LIU T X, WANG M J, et al. SRSF1-dependent alternative splicing attenuates BIN1 expression in non-small cell lung cancer[J]. J Cell Biochem, 2020, 121(2): 946-953. doi: 10.1002/jcb.v121.2
[21]	BARBAGALLO D, CAPONNETTO A, BREX D, et al. CircSMARCA5 regulates VEGFA mRNA splicing and angiogenesis in glioblastoma multiforme through the binding of SRSF1[J]. Cancers (Basel), 2019, 11(2): E194.
[22]	ZHANG X T, ZOU G Y, LI X Y, et al. An isoflavone derivative potently inhibits the angiogenesis and progression of triple-negative breast cancer by targeting the MTA2/SerRS/VEGFA pathway[J]. Cancer Biol Med, 2020, 17(3): 693-706. doi: 10.20892/j.issn.2095-3941.2020.0010
[23]	LU J, WANG Y H, YOON C, et al. Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis[J]. Cancer Lett, 2020, 471: 38-48. doi: 10.1016/j.canlet.2019.11.038
[24]	HAMDOLLAH ZADEH M A, AMIN E M, HOAREAU-AVEILLA C, et al. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance[J]. Mol Oncol, 2015, 9(1): 167-178. doi: 10.1016/j.molonc.2014.07.017
[25]	ABNET C C, ARNOLD M, WEI W Q. Epidemiology of esophageal squamous cell carcinoma[J]. Gastroenterology, 2018, 154(2): 360-373. doi: 10.1053/j.gastro.2017.08.023

SRSF1 expression	ESCC tissues (n=40)	Matched paracancerous tissues (n=40)	χ²	P value
Low	13 (32.5)	24 (60.0)	6.084	0.013 6
High	27 (67.5)	16 (40.0)